Science 37 Holdings, Inc.

NasdaqCM:SNCE Stock Report

Market Cap: US$34.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Science 37 Holdings Management

Management criteria checks 2/4

Science 37 Holdings' CEO is Dave Coman, appointed in Nov 2019, has a tenure of 4.33 years. total yearly compensation is $8.06M, comprised of 6.8% salary and 93.2% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $309.55K. The average tenure of the management team and the board of directors is 3.3 years and 2.4 years respectively.

Key information

Dave Coman

Chief executive officer

US$8.1m

Total compensation

CEO salary percentage6.82%
CEO tenure4.3yrs
CEO ownership0.9%
Management average tenure3.3yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Analysis Article Dec 18

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

With a price-to-sales (or "P/S") ratio of 0.5x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) may be sending very bullish...
Analysis Article Apr 17

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

You may think that with a price-to-sales (or "P/S") ratio of 0.6x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) is...
Seeking Alpha Aug 18

Science 37, Syapse team for faster patient enrollment in cancer trials

Science 37 (NASDAQ:SNCE) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process. "By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors," said Science 37 Chief Medical Officer Jonathan Cotliar.
Seeking Alpha Aug 11

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 press release (NASDAQ:SNCE): Q2 GAAP EPS of -$0.05 beats by $0.19. Revenue of $19.3M (+53.8% Y/Y) misses by $0.2M. Net bookings were $25.4M for the quarter ended June 30, 2022, compared to $44.1M for the same period in 2021. Adjusted EBITDA was -$16.5M for the quarter ended June 30, 2022, compared to -$5.4M in the same period in 2021.  Science 37 is providing revenue guidance of $76 million to $86 million vs. consensus of $92.24M and adjusted EBITDA guidance of $(65) million to $(69) million for the fiscal year ending December 31, 2022.
Analysis Article May 13

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a sad week for Science 37 Holdings, Inc. ( NASDAQ:SNCE ), who've watched their investment drop 20% to US$3.03...
Analysis Article Apr 11

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha Jan 02

Science 37: Pioneering Decentralized Clinical Trials

Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs. The Company is a leader in its niche DCT market worth over $60 billion.
Analysis Article Nov 04

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Dave Coman's remuneration changed compared to Science 37 Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$125m

Jun 30 2023n/an/a

-US$134m

Mar 31 2023n/an/a

-US$121m

Dec 31 2022US$8mUS$550k

-US$51m

Sep 30 2022n/an/a

-US$50m

Jun 30 2022n/an/a

-US$41m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$8mUS$435k

-US$94m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$400k

-US$32m

Compensation vs Market: Dave's total compensation ($USD8.06M) is above average for companies of similar size in the US market ($USD662.89K).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


CEO

Dave Coman (53 yo)

4.3yrs
Tenure
US$8,062,854
Compensation

Mr. David Coman, also known as Dave, has been Chief Executive Officer of Science 37 Holdings, Inc. (formerly known as Science 37, Inc.) since November 2019 and serves as its Director since October 2021. He...


Leadership Team

NamePositionTenureCompensationOwnership
David Coman
CEO & Director4.3yrsUS$8.06m0.89%
$ 309.5k
Christine Pellizzari
Chief Legal & Human Resources Officer and Secretary2.7yrsUS$4.65m0.24%
$ 83.4k
Darcy Forman
Chief Delivery Officer4.2yrsUS$3.93m0.26%
$ 90.6k
Mike Zaranek
Chief Financial Officer3.9yrsno data0.15%
$ 52.2k
Irena Lambridis
VP and Head of Quality Assurance & Complianceless than a yearno datano data
Margie Kooman
Vice President of Marketing & Communications3.8yrsno datano data
Drew Bustos
Chief Strategy & Marketing Officerno datano datano data
Jonathan Cotliar
Chief Medical Officer4.8yrsUS$486.60k0.69%
$ 240.9k
Michael Shipton
Chief Commercial Officer1.5yrsno data0.059%
$ 20.4k
Tyler Van Horn
VP of Corporate Strategy & Chief of Staff2.2yrsno datano data
Erica Prowisor
Senior VP of Patient & Provider Networksless than a yearno datano data
3.3yrs
Average Tenure
51.5yo
Average Age

Experienced Management: SNCE's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Coman
CEO & Director2.4yrsUS$8.06m0.89%
$ 309.5k
John Hubbard
Independent Director3.5yrsUS$180.00k0.034%
$ 11.8k
Robert Faulkner
Independent Chairman of the Board2.4yrsUS$215.00k0.034%
$ 11.8k
Paul von Autenried
Independent Director1.5yrsUS$93.33k0.038%
$ 13.2k
Bhooshitha De Silva
Independent Director2.4yrsno datano data
Neil Tiwari
Independent Director2.4yrsUS$165.00k0.034%
$ 11.8k
Emily Rollins
Independent Director2.4yrsUS$185.00k0.034%
$ 11.8k
2.4yrs
Average Tenure
53yo
Average Age

Experienced Board: SNCE's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/11 22:23
End of Day Share Price 2024/03/11 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Science 37 Holdings, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Matthew HewittCraig-Hallum Capital Group LLC
Frank TakkinenLake Street Capital Markets, LLC